- Joined
- 27 June 2010
- Posts
- 4,225
- Reactions
- 337
Chimeric Therapeutics is a biotechnology company developing a breakthrough cancer cell therapy drug which was discovered at the prestigious City of Hope Cancer Centre in Los Angeles, California.
Chimeric antigen receptor (CAR) T Cell therapy is regarded as one of the most promising areas of cancer research today. CAR T cell therapy is a commercially relevant and powerful therapeutic modality that engineers a patient's T cells to establish de novo antitumor immunity targeting cancer cells. The technology has generated high clinical response rates primarily in blood cancers. The first CAR T cell products have been recently approved by the FDA for the treatment of leukaemia and lymphoma.
Chimeric's CAR T technology, known as CTLX-CAR T, has completed many years of pre-clinical research and in September 2020 dosing of patients with glioblastoma (brain cancer) commenced as part of Phase 1 clinical trials at City of Hope Cancer Centre in Los Angeles.
Chimeric has the worldwide exclusive licence to technology from City of Hope pursuant to a Licence Agreement.
It is anticipated that CHM will list on the ASX during January 2021.
Chimeric antigen receptor (CAR) T Cell therapy is regarded as one of the most promising areas of cancer research today. CAR T cell therapy is a commercially relevant and powerful therapeutic modality that engineers a patient's T cells to establish de novo antitumor immunity targeting cancer cells. The technology has generated high clinical response rates primarily in blood cancers. The first CAR T cell products have been recently approved by the FDA for the treatment of leukaemia and lymphoma.
Chimeric's CAR T technology, known as CTLX-CAR T, has completed many years of pre-clinical research and in September 2020 dosing of patients with glioblastoma (brain cancer) commenced as part of Phase 1 clinical trials at City of Hope Cancer Centre in Los Angeles.
Chimeric has the worldwide exclusive licence to technology from City of Hope pursuant to a Licence Agreement.
It is anticipated that CHM will list on the ASX during January 2021.